Prevention of Renal Complications of Diabetes With Thiamine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01725412|
Recruitment Status : Unknown
Verified November 2012 by Gudrun Caspar-Bell, University of Saskatchewan.
Recruitment status was: Not yet recruiting
First Posted : November 12, 2012
Last Update Posted : November 12, 2012
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathy||Dietary Supplement: Thiamine 300mg PO once daily Dietary Supplement: placebo||Phase 4|
Thiamine (vitamin B1) is a water-soluble vitamin. It is absorbed from the gastrointestinal tract and taken up into tissues by transport proteins and converted to thiamine pyrophosphate (TPP) by thiamine pyrophosphokinase (TPPK). TPP is a co-factor of pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase and transketolase (TKT)—enzymes involved in the metabolism of glucose.
Various transport proteins are involved in the transport of thiamine monophosphate (TMP) and TPP across membranes. These include thiamine transported isoform-1 (THTR1) and thiamine transporter isoform-2 (THTR2), reduced folate carrier-1 (RFC-1), which transports TMP and TPP across cell plasma membranes and the mitochondrial TPP transporter (mTHTR). Thiamine and TMP/TPP transporters may have abnormal expression in diabetes. Increased THTR1 levels are found in red blood cells (RBCs) and mononuclear leucocytes of patients with diabetes compared to those of healthy subjects. RBC precursors and leucocytes appeared to up-regulate THTR1 expression in response to decreased thiamine availability. In the presence of hyperglycemia, renal tubular epithelial cells, by contrast, have decreased expression. In both experimental models of diabetes and in human diabetics increased clearance of thiamine has been demonstrated. This precedes the development of microalbuminuria. Patients with microalbuminuria and early decline in glomerular filtration rate had higher fractional excretion of thiamine compared to patients with stable renal function.
Thiamine supplementation in STZ- diabetic mice prevented the development of microalbuminuria, decreasing urinary albumin excretion (UAE) by approximately 80%. In addition thiamine supplementation prevented diuresis and glycosuria. Human studies are limited but in one placebo controlled study the thiamine group showed a significant decrease in microalbuminuria in diabetic patients on thiamine.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Study Start Date :||November 2012|
|Estimated Primary Completion Date :||June 2013|
|Experimental: Thiamine Supplementation||
Dietary Supplement: Thiamine 300mg PO once daily
|Placebo Comparator: Placebo||
Dietary Supplement: placebo
- Serum Thiamine Level
- Urinary Thiamine Level
- Inflammatory MarkersE-selectin, Intercellular Adhesion Molecule 1, von Willebrand Factor, malondialdehyde, glutathione, homocysteine, isoprotein F21, advanced glycation endproducts, receptor for advanced glycation endproducts
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01725412
|Contact: Gudrun Caspar-Bell, MD||306 966-2044||Gudrun.email@example.com|
|Contact: Benjamin M Sehmer, MB||306 261 firstname.lastname@example.org|
|Royal University Hospital|
|Saskatoon, Saskatchewan, Canada, S7K 0M7|
|Contact: Gudrun Caspar-Bell|
|Principal Investigator:||Dr. Gudrun Caspar-Bell, MD||University of Saskatchewan|